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Recent studies have found different microbiota and chem-
ical milieus in different healthy skin areas. In addition, 
topographically distinct immune and barrier character-
istics have been identified (1–3). Based on these results, 
the skin cannot be considered a unified organ: 3 different 
skin niches can be distinguished: sebaceous gland poor 
(SGP), sebaceous gland rich (SGR), and apocrine gland 
rich (AGR) skin regions (1, 3). Certain immune-mediated 
skin diseases localize primarily to one of these regions; for 
example, atopic dermatitis appears mostly in SGP regions, 
acne and rosacea appear in SGR regions, and hidradenitis 
suppurativa in AGR regions. 
Other skin diseases can develop in any skin regions, 
like psoriasis, where lesions can manifest in either SGP 
regions (psoriasis vulgaris of SGP skin), or SGR regions 
(scalp psoriasis), and AGR regions (inverse psoriasis). 
This study aimed to compare the immune and barrier 
features of psoriasis localized to SGP areas (psoriasis 
vulgaris) and psoriasis on SGR regions (scalp psoriasis), 
to determine if the immune milieu of healthy skin influ-
ences the immune characteristics and, consequently, the 
treatment of psoriasis on distinct skin regions. 
METHODS AND RESULTS
Since psoriasis is a T helper (Th)1/Th17-mediated skin disorder 
(4), the current study investigated the Th1- and Th17-related im-
mune and barrier alterations in lesional skin samples of patients 
with psoriasis vulgaris on SGP skin and scalp psoriasis (each n = 6) 
(Table SI1) by immunohistochemistry and RT-qPCR (for details 
see Appendix S11). 
Immunostaining of CD4+ T cells, CD11c+ myeloid dendritic 
cells (mDCs) and CD1a+ Langerhans cells (LCs) revealed no 
significant differences between psoriasis vulgaris on SGP skin 
and scalp psoriasis on SGR skin (Fig. S11). 
Gene expression levels for Th1- and Th17-related cytokines, 
as interferon (IFN)γ, IL-12, IL-17 and IL-23 were similar (Table 
SII1), and the protein levels of IFNγ, IL-17 and IL-23 were also 
similar between the 2 groups. No differences in the Th17-related 
chemokines, CCL2 and CCL20, were detected at the mRNA level 
(Table SII1). In contrast, the protein expression of CCL20 was 
significantly higher in scalp psoriasis compared with psoriasis 
vulgaris of SGP skin (Table SII1, Fig. S21). 
Expression of the most common pro-inflammatory cytokines, 
IL-1β and tumour necrosis factor alpha (TNF-α), was investigated 
at the mRNA level, while immunostaining for TNF-α was also 
performed. Their expression at the mRNA level (Table SII1) and 
TNF-α protein levels were similar in the 2 psoriatic sample groups 
(Table SII1, Fig. S21). 
To further investigate the Th17-related components of the innate 
immune response, this study assessed the gene expression levels 
of different AMPs (S100A7/8/9, human beta defensin (DEFB)4B, 
lipocalin (LCN)2), and protein levels for LCN2 and S100A8. There 
were no significant differences between the 2 psoriatic groups, at 
either gene or protein levels (Table SII1, Fig. S31), except for the 
gene expression of LCN2, which was significantly higher in scalp 
psoriasis (Table SII1).
Finally, the mRNA levels of key molecules involved in the for-
mation and maintenance of the epidermal barrier (loricrin (LOR), 
filaggrin (FLG), keratin (KRT) 6, KRT17) were also examined by 
qPCR, while LOR, FLG, and KRT17 were evaluated, using im-
munohistochemistry. Expression of these molecules was similar 
in psoriasis samples from SGR and SGP skin, at both gene and 
protein levels (Table SII1, Fig. S31).
DISCUSSION
This study compared the immune characteristics of pso-
riasis vulgaris on SGP skin and scalp psoriasis on SGR 
skin to determine whether the inflammation developed in 
the 2 subtypes of psoriasis are influenced by the primarily 
distinct immune milieu of the different healthy skin areas. 
The results show that the mediators of both innate immune 
responses and Th1/Th17 type adaptive immune pathways 
were expressed similarly in scalp psoriasis and psoriasis 
vulgaris of SGP skin (Fig. 1). In addition, no significant 
differences could be detected in the expression of barrier 
molecules (Fig. 1). Significant differences were found 
only in LCN2 mRNA and CCL20 protein expression, with 
higher levels in scalp psoriasis. Since these parameters 
have previously been shown to be elevated even in heal-
thy SGR skin compared with SGP (3), these differences 
may reflect the original immune characteristics of SGR 
skin region rather than psoriasis-related features (Fig. 1).
The immune characteristics of psoriasis in different skin 
areas have been compared in a few publications (5–9), 
but only 2 publications have focused on comparing scalp 
psoriasis and psoriasis vulgaris (5, 6). The research focus 
and applied methods of these 2 studies were different from 
ours; furthermore, barrier components were not examined 
at the protein level (5, 6). Moreover, the conclusions of 
these 2 articles appear to be contradictory. In general, the 
results of the current study are in line with that of Ruano 
and colleagues (5), who, despite revealing some diffe-
rences in the magnitude of dysregulation between the 2 
forms of psoriasis by transcriptomic analyses, concluded 
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that the immune mechanisms of scalp psoriasis are fun-
damentally similar to that of skin psoriasis (5). In another 
study, Ahn et al. concluded that distinct psoriasis subtypes 
display differences in IL-17, IFN-γ and IL-22 production 
(6). Although these results appear to be contrary to ours, 
these differences were significant only when palmoplantar 
psoriasis were compared with conventional plaque pso-
riasis (6). In another publication, chronic plaque psoriasis 
and inverse psoriasis, characteristic of AGR skin, were 
compared, and IL-17 was identified as their major shared 
pathway (9). These results support our findings showing 
that psoriasis localized to different skin areas share similar 
IL-17 related immune characteristics.
In clinical practice, the treatment of scalp psoriasis is 
considered more difficult than that of psoriasis vulgaris 
on SGP skin, since the high density of hair follicles and 
pilosebaceous units makes the application of local therapy 
and phototherapy technically complicated. Therefore, 
new formulations, such as foam or gel, were developed 
as new treatment modalities for this region (10). Clinical 
practice and studies show that biological treatments have 
the same efficacy for psoriasis vulgaris and scalp psoriasis 
(11). These findings are supported by the current study, 
showing that, in spite of the significant differences bet-
ween healthy SGR and SGP skin immune milieu, psoriatic 
plaques developing on these distinct areas bear similar 
cellular, molecular, and barrier characteristics (Fig. 1). In 
summary, the results of this study suggest that, although 
the formulation of the local therapy needs to be different 
for psoriasis localized to the scalp vs SGP skin areas, there 
is no indication for the development of active ingredients 
with different mechanisms of action.
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Fig. 1. Although the immune and barrier characteristics of healthy 
sebaceous gland poor (SGP) and sebaceous gland rich (SGR) skin are 
different, the psoriatic plaques developing on these distinct areas 
bear similar cellular, molecular and barrier characteristics. AMP: 
antimicrobial peptide; CCL: chemokine (C-C motif) ligand; hBD2: human 
beta defensin2; FLG: filaggrin; IFNG: interferon gamma; IL: interleukin; KR: 
keratin; LCN: lipocalin; LOR: loricrin; TNFA: tumour necrosis factor alpha.
